Ranbaxy Internal Audit Disclosure Highlights FDA Policy Exceptions

FDA went to court for a look at Ranbaxy’s internal audits despite its longstanding policy against routinely reviewing such documents. However, a 1996 revision made exceptions for cases like Ranbaxy’s, in which the agency is pursuing allegations of fraud.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet